The influence of insulin and incretin-based therapies on renal tubular transport.
Electrolytes handling
Glucagon-like peptide-1
Insulin
Serine protease dipeptidyl peptidase-4
Tubular transport
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
08
02
2024
accepted:
21
07
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
21
8
2024
Statut:
aheadofprint
Résumé
The tubular function of the kidney is very complex and is finely regulated by many factors. These include a variety of hormonal signaling pathways which are involved in the expression, activation and regulation of renal transporters responsible for the handling of electrolytes. Glucose-lowering drugs such as insulin and incretin-based therapies, exert a well-known renal protective role in diabetic kidney disease, mainly acting at the glomerular level. In the literature, several studies have described the effect of insulin and the incretin hormones on tubular transport. Most of these studies focused on the variations in excretion and clearance of sodium but did not extensively and systematically investigate the possible variations that these hormones may induce in the tubular regulation of all the other electrolytes, urea metabolism, acid-base balance and urinary pH. While insulin action on the kidney is very well-described, the renal tubular impact of incretin-based therapies is less consistent and the results available are scarce. To our knowledge, this is the first review summarizing the effects induced on renal tubules by insulin, glucagon-like peptide-1 (GLP-1) receptor agonists and serine protease dipeptidyl peptidase-4 (DPP4) inhibitors in both healthy and diabetic human subjects. This is significant because it highlights the existence of a renal-gut and pancreas axis which also has a direct tubular effect and enables a deeper understanding of renal physiology.
Identifiants
pubmed: 39167349
doi: 10.1007/s40620-024-02048-w
pii: 10.1007/s40620-024-02048-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Vallon V (2009) Micropuncturing the nephron. Pflugers Arch 458(1):189–201. https://doi.org/10.1007/s00424-008-0581-7
doi: 10.1007/s00424-008-0581-7
pubmed: 18752000
Pina AF et al (2020) Insulin: Trigger and Target of Renal Functions. Front Cell Dev Biol 8:519. https://doi.org/10.3389/fcell.2020.00519
doi: 10.3389/fcell.2020.00519
pubmed: 32850773
pmcid: 7403206
Tiwari S, Riazi S, Ecelbarger CA (2007) Insulin’s impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol 293(4):F974-984. https://doi.org/10.1152/ajprenal.00149.2007
doi: 10.1152/ajprenal.00149.2007
pubmed: 17686957
DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ (1975) The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 55(4):845–855. https://doi.org/10.1172/JCI107996
doi: 10.1172/JCI107996
pubmed: 1120786
pmcid: 301822
di Giuseppe G et al (2021) Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences. Minerva Endocrinol (Torino) 46(3):272–292. https://doi.org/10.23736/S2724-6507.21.03405-9
doi: 10.23736/S2724-6507.21.03405-9
pubmed: 34218657
Mezza T, Cinti F, Cefalo CMA, Pontecorvi A, Kulkarni RN, Giaccari A (2019) β-cell fate in human insulin resistance and type 2 diabetes: a perspective on islet plasticity. Diabetes 68(6):1121–1129. https://doi.org/10.2337/db18-0856
doi: 10.2337/db18-0856
pubmed: 31109941
pmcid: 6905483
Mezza T et al (2014) Insulin resistance alters islet morphology in nondiabetic humans. Diabetes 63(3):994–1007. https://doi.org/10.2337/db13-1013
doi: 10.2337/db13-1013
pubmed: 24215793
pmcid: 3931397
Mezza T et al (2018) Increased β-cell workload modulates proinsulin-to-insulin ratio in humans. Diabetes 67(11):2389–2396. https://doi.org/10.2337/db18-0279
doi: 10.2337/db18-0279
pubmed: 30131390
Brusco N et al (2023) Intra-islet insulin synthesis defects are associated with endoplasmic reticulum stress and loss of beta cell identity in human diabetes. Diabetologia 66(2):354–366. https://doi.org/10.1007/s00125-022-05814-2
doi: 10.1007/s00125-022-05814-2
pubmed: 36280617
Nauck MA, Quast DR, Wefers J, Pfeiffer AFH (2021) The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab 23(Suppl 3):5–29. https://doi.org/10.1111/dom.14496
doi: 10.1111/dom.14496
pubmed: 34310013
Holst JJ (2019) The incretin system in healthy humans: The role of GIP and GLP-1. Metabolism 96:46–55. https://doi.org/10.1016/j.metabol.2019.04.014
doi: 10.1016/j.metabol.2019.04.014
pubmed: 31029770
Makino Y, Fujita Y, Haneda M (2015) Dipeptidyl peptidase-4 inhibitors in progressive kidney disease. Curr Opin Nephrol Hypertens 24(1):67–73. https://doi.org/10.1097/MNH.0000000000000080
doi: 10.1097/MNH.0000000000000080
pubmed: 25415611
Di Giuseppe G et al (2023) First-phase insulin secretion: can its evaluation direct therapeutic approaches? Trends Endocrinol Metab 34(4):216–230. https://doi.org/10.1016/j.tem.2023.02.001
doi: 10.1016/j.tem.2023.02.001
pubmed: 36858875
Crajoinas RO et al (2011) Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 301(2):F355-363. https://doi.org/10.1152/ajprenal.00729.2010
doi: 10.1152/ajprenal.00729.2010
pubmed: 21593184
Gutzwiller J-P et al (2004) Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89(6):3055–3061. https://doi.org/10.1210/jc.2003-031403
doi: 10.1210/jc.2003-031403
pubmed: 15181098
Tsimihodimos V, Elisaf M (2018) Effects of incretin-based therapies on renal function. Eur J Pharmacol 818:103–109. https://doi.org/10.1016/j.ejphar.2017.10.049
doi: 10.1016/j.ejphar.2017.10.049
pubmed: 29066413
Friedberg CE, Koomans HA, Bijlsma JA, Rabelink TJ, Dorhout Mees EJ (1991) Sodium retention by insulin may depend on decreased plasma potassium. Metabolism 40(2):201–204. https://doi.org/10.1016/0026-0495(91)90175-v
doi: 10.1016/0026-0495(91)90175-v
pubmed: 1988777
Skøtt P et al (1989) Effects of insulin on kidney function and sodium excretion in healthy subjects. Diabetologia. https://doi.org/10.1007/BF00274259
doi: 10.1007/BF00274259
pubmed: 2676669
Gans RO, Toom L, Bilo HJ, Nauta JJ, Heine RJ, Donker AJ (1991) Renal and cardiovascular effects of exogenous insulin in healthy volunteers. Clin Sci (London, England: 1979). https://doi.org/10.1042/cs0800219
doi: 10.1042/cs0800219
ter Maaten JC, Bakker SJ, Serné EH, ter Wee PM, Donker AJ, Gans RO (1999) Insulin’s acute effects on glomerular filtration rate correlate with insulin sensitivity whereas insulin’s acute effects on proximal tubular sodium reabsorption correlation with salt sensitivity in normal subjects. Nephrol Dial Transplant 14(10):2357–2363. https://doi.org/10.1093/ndt/14.10.2357
doi: 10.1093/ndt/14.10.2357
pubmed: 10528658
ter Maaten JC, Bakker SJ, Serné EH, Donker AJ, Gans RO (2001) Renal sodium handling and haemodynamics are equally affected by hyperinsulinaemia in salt-sensitive and salt-resistant hypertensives. J Hypertens 19(9):1633–1641. https://doi.org/10.1097/00004872-200109000-00016
doi: 10.1097/00004872-200109000-00016
pubmed: 11564984
Skøtt P et al (1991) Effect of insulin on renal sodium handling in hyperinsulinaemic type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance. Diabetologia 34(4):275–281. https://doi.org/10.1007/BF00405088
doi: 10.1007/BF00405088
pubmed: 2065862
Pelikánová T, Smrcková I, Krízová J, Stríbrná J, Lánská V (1996) Effects of insulin and lipid emulsion on renal haemodynamics and renal sodium handling in IDDM patients. Diabetologia 39(9):1074–1082. https://doi.org/10.1007/BF00400657
doi: 10.1007/BF00400657
pubmed: 8877292
Gutzwiller J-P et al (2006) Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73(2–3):142–150. https://doi.org/10.1159/000094334
doi: 10.1159/000094334
pubmed: 16809911
Skov J et al (2013) Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 98(4):E664-671. https://doi.org/10.1210/jc.2012-3855
doi: 10.1210/jc.2012-3855
pubmed: 23463656
Pechere-Bertschi A, Sunaric-Megevand G, Haefliger I, Panarello F, Maillard M, Burnier M (2007) Renal sodium handling in patients with normal pressure glaucoma. Clin Sci (Lond) 112(6):337–344. https://doi.org/10.1042/CS20060082
doi: 10.1042/CS20060082
pubmed: 17014421
Seidlerová J et al (2006) Association between arterial properties and renal sodium handling in a general population. Hypertension 48(4):609–615. https://doi.org/10.1161/01.HYP.0000240516.60040.ba
doi: 10.1161/01.HYP.0000240516.60040.ba
pubmed: 16966578
Shirley DG, Walter SJ, Noormohamed FH (2002) Natriuretic effect of caffeine: assessment of segmental sodium reabsorption in humans. Clin Sci (Lond) 103(5):461–466. https://doi.org/10.1042/cs1030461
doi: 10.1042/cs1030461
pubmed: 12401118
Asmar A et al (2015) Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am J Physiol Endocrinol Metab 308(8):E641-649. https://doi.org/10.1152/ajpendo.00429.2014
doi: 10.1152/ajpendo.00429.2014
pubmed: 25670826
Asmar A et al (2019) Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1-renal axis in man. J Clin Endocrinol Metab 104(7):2509–2519. https://doi.org/10.1210/jc.2019-00004
doi: 10.1210/jc.2019-00004
pubmed: 30835273
Asmar A et al (2021) The renal extraction and the natriuretic action of GLP-1 in humans depend on interaction with the GLP-1 receptor. J Clin Endocrinol Metab 106(1):e11–e19. https://doi.org/10.1210/clinem/dgaa643
doi: 10.1210/clinem/dgaa643
pubmed: 32927478
Muskiet MHA et al (2016) Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes Metab 18(2):178–185. https://doi.org/10.1111/dom.12601
doi: 10.1111/dom.12601
pubmed: 26636423
Pyke C et al (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155(4):1280–1290. https://doi.org/10.1210/en.2013-1934
doi: 10.1210/en.2013-1934
pubmed: 24467746
Asmar A et al (2016) Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. Am J Physiol Endocrinol Metab 310(9):E744-753. https://doi.org/10.1152/ajpendo.00518.2015
doi: 10.1152/ajpendo.00518.2015
pubmed: 26956188
Tonneijck L et al (2016) Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia 59(7):1412–1421. https://doi.org/10.1007/s00125-016-3938-z
doi: 10.1007/s00125-016-3938-z
pubmed: 27038451
pmcid: 4901099
Skov J et al (2016) Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab 18(6):581–589. https://doi.org/10.1111/dom.12651
doi: 10.1111/dom.12651
pubmed: 26910107
Tonneijck L et al (2017) Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: an 8-week, randomised, open-label trial. Diabetes Obes Metab 19(12):1669–1680. https://doi.org/10.1111/dom.12985
doi: 10.1111/dom.12985
pubmed: 28449402
Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ (2015) Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 38(1):132–139. https://doi.org/10.2337/dc14-1958
doi: 10.2337/dc14-1958
pubmed: 25414155
Tonneijck L et al (2016) Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 39(11):2042–2050. https://doi.org/10.2337/dc16-1371
doi: 10.2337/dc16-1371
pubmed: 27585605
Lovshin JA et al (2017) Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1α1-67 in patients with type 2 diabetes. Diabetes Care 40(8):1073–1081. https://doi.org/10.2337/dc17-0061
doi: 10.2337/dc17-0061
pubmed: 28550195
Palmer BF et al (2021) Clinical management of hyperkalemia. Mayo Clin Proc 96(3):744–762. https://doi.org/10.1016/j.mayocp.2020.06.014
doi: 10.1016/j.mayocp.2020.06.014
pubmed: 33160639
Abate N, Chandalia M, Cabo-Chan AV, Moe OW, Sakhaee K (2004) The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65(2):386–392. https://doi.org/10.1111/j.1523-1755.2004.00386.x
doi: 10.1111/j.1523-1755.2004.00386.x
pubmed: 14717908